ライフサイエンスコーパス: HIV protease inhibitor

1 e and robust classification of resistance to HIV protease inhibitors.

2 on glucose transport were observed for other HIV protease inhibitors.

3 d the urgent need for a second generation of HIV protease inhibitors.

4 (3)-P(2) position of hydroxyethylamine-based HIV protease inhibitors.

5 al protease increase the binding affinity of HIV protease inhibitors.

6 of HIV with resistance to a wide variety of HIV protease inhibitors.

7 now being used and the more frequent use of HIV protease inhibitors.

8 useful for designing specific and efficient HIV protease inhibitors.

9 10 pi-aromatic system of Ro 31-8959 class of HIV protease inhibitors.

10 compound for further development of May1 and HIV protease inhibitors.

11 roviral drugs, such as efavirenz and boosted HIV protease inhibitors.

12 Compound 2a is a key intermediate toward HIV protease inhibitors.

13 ituent effects to the analysis and design of HIV protease inhibitors.

14 of epi-aortic lesions in patients receiving HIV protease inhibitors.

15 ease in HIV-1 infected patients treated with HIV protease inhibitors.

16 atives could have potential use as effective HIV protease inhibitors.

17 fragment to fill S1' and S2' afforded potent HIV protease inhibitor 49 [IC50 = 10 nM, 3-[(2-tert-buty

18 are amino alcohol 1, the core portion of the HIV protease inhibitor A-792611, in 46% yield from pheny

19 an immunodeficiency virus (HIV) treated with HIV protease inhibitors, a complication develops that re

20 HIV protease inhibitors acutely block glucose transporte

21 iseases like atherosclerosis it appears that HIV protease inhibitors affect the cardiovascular system

22 The HIV protease inhibitor amprenavir inhibits calpain activ

23 ed that peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, alt

24 We also resolved binding of zinc, lipids and HIV protease inhibitors and showed that drug binding blo

25 poor pharmacokinetic properties of existing HIV protease inhibitors and, potentially, other drug cla

26 Ritonavir is a human immunodeficiency virus (HIV) protease inhibitor and an inhibitor of cytochrome P

27 with three probes (a thrombin inhibitor, an HIV protease inhibitor, and a model for angiotensin II).

28 HIV protease inhibitors are a key component of anti-retr

29 ation of a series of nonpeptidic macrocyclic HIV protease inhibitors are described.

30 tructure-based design and synthesis of novel HIV protease inhibitors are described.

31 nd synthesis of a series of novel nonpeptide HIV protease inhibitors are described.

32 Interestingly, HIV protease inhibitors are distinct from previously kno

33 HIV protease inhibitors are thus a new class of anticanc

34 (RTV)-boosted human immunodeficiency virus (HIV) protease inhibitors are coadministered in healthy v

35 We conclude that HIV protease inhibitors as a class are capable of select

36 or the discovery of more potent non-peptidic HIV protease inhibitors as potential therapeutic agents

37 We identified that two HIV protease inhibitors, atazanavir and saquinavir, in c

38 poorly soluble human immunodeficiency virus (HIV) protease inhibitor based upon in vivo test results.

39 . 2c) were identified as potent, nonpeptidic HIV protease inhibitors, but these compounds lacked sign

40 e made the intriguing discovery that several HIV-protease inhibitors can function as decoy antigens t

41 The HIV protease inhibitor class of antiretroviral drug caus

42 f lopinavir, a human immunodeficiency virus (HIV) protease inhibitor, coformulated with ritonavir as

43 Crystallographic studies of HIV protease-inhibitor complexes help explain the perhap

44 inhibitors, utilizing crystal structures of HIV protease/inhibitor complexes, provided a rational ba

45 Computational modeling revealed that HIV-protease inhibitors comprised structural features pr

46 of (2R)-indandiol, a chiral precursor of the HIV protease inhibitor, Crixivan.

47 we tested the hypothesis that indinavir, an HIV-protease inhibitor, directly induces insulin resista

48 s an illustration, the core structure of the HIV protease inhibitors DMP 323 and DMP 450 has been pre

49 ding lupus medications, thrombin inhibitors, HIV protease inhibitors, DNA gyrase inhibitors and many

50 or the progeria-like side effects of certain HIV protease inhibitor drugs, but also highlight new app

51 tically, we found that, across the family of HIV protease inhibitors, efficacy correlated with integr

52 ination antiretroviral therapy that includes HIV protease inhibitors experience atrophy of peripheral

53 rying mutations known to cause resistance to HIV protease inhibitors faithfully recapitulated the rep

54 ed the safety and efficacy of saquinavir, an HIV-protease inhibitor, given with one or two nucleoside

55 Since HIV protease inhibitors have "off target" cellular effec

56 d rapid biliary excretion of peptide-derived HIV protease inhibitors have limited their utility as po

57 Human immunodeficiency virus (HIV) protease inhibitors have been successfully used in

58 HIV protease inhibitors (HIV PI) are a class of antiretr

59 HIV protease inhibitors (HIV-PIs) are key components of

60 HIV protease inhibitors (HIV-PIs) target the HIV asparty

61 Inhibitors of the HIV aspartyl protease [HIV protease inhibitors (HIV-PIs)] are the cornerstone o

62 Human immunodeficiency virus (HIV) protease inhibitors (HIV PIs) are the core componen

63 The HIV protease inhibitors (HPI) amprenavir, nelfinavir, an

64 and diabetes are recognized side effects of HIV protease inhibitors (HPIs), suggesting that these ag

65 he present study, we examined the effects of HIV protease inhibitors in female LDL-R null mice.

66 cal approaches used to determine the role of HIV protease inhibitors in the development of cardiovasc

67 bitors, the AlphaLISA assay confirmed all 11 HIV protease inhibitors in the library capable of suppre

68 trials have established the critical role of HIV protease inhibitors in the treatment of acquired imm

69 fectiveness of human immunodeficiency virus (HIV) protease inhibitors in acquired immunodeficiency sy

70 of non-peptide human immunodeficiency virus (HIV) protease inhibitors in short analysis time and auto

71 block for several clinical and experimental HIV protease inhibitors including the highly important d

72 ause for the loss of sensitivity toward many HIV protease inhibitors, including our first-generation

73 ease, monofluorinated analogues of the Merck HIV protease inhibitor indinavir, are described.

74 We demonstrate that the HIV protease inhibitor, indinavir, dramatically inhibits

75 sity lipoprotein receptor (LDL-R) null mice, HIV protease inhibitors induce atherosclerotic lesions a

76 t role in the gender differences observed in HIV protease inhibitor-induced atherosclerosis.

77 er, the cellular/molecular mechanisms of the HIV protease inhibitor-induced lipid dysregulation and a

78 chemotherapeutic agents, antipsychotics, and HIV protease inhibitors, into and out of the central ner

79 The clinical use of HIV protease inhibitors is associated with insulin resis

80 Treatment of patients infected with HIV with HIV protease inhibitors is unfortunately associated with

81 In vitro and in vivo data suggest that the HIV protease inhibitors lopinavir/ritonavir may have pot

82 Poor adherence to HIV protease inhibitors may compromise the effectiveness

83 iscuss possible molecular mechanisms whereby HIV protease inhibitors may promote atherogenesis.

84 In conclusion, HIV protease inhibitors may, by blocking the caspase-dep

85 Notably, Indinavir; an HIV protease inhibitor, may be effective in reducing the

86 rrently available data strongly suggest that HIV protease inhibitors negatively impact the cardiovasc

87 ivity of Ddi2 either genetically or with the HIV protease inhibitor nelfinavir increased its binding

88 The HIV protease inhibitor nelfinavir is currently being ana

89 The HIV-protease inhibitor nelfinavir has shown broad antica

90 macologically recapitulated by combining the HIV-protease inhibitor nelfinavir with ISRIB, an experim

91 We investigated the effects of HIV protease inhibitors on adipogenesis and adipocyte su

92 on mass spectrometry to study the effects of HIV protease inhibitors on the human zinc metalloproteas

93 sed in vitro and in vivo models to show that HIV protease inhibitor (PI) class ARVs induced neuronal

94 GS-8374 is a potent HIV protease inhibitor (PI) with a unique diethyl-phosph

95 an allophenylnorstatine-containing dipeptide HIV protease inhibitor (PI), which is potent against a w

96 s a once-daily human immunodeficiency virus (HIV) protease inhibitor (PI) shown to be effective and w

97 a nonpeptidic human immunodeficiency virus (HIV) protease inhibitor (PI), containing 3(R),3a(S),6a(R

98 Human immunodeficiency virus (HIV) protease inhibitor (PI)-induced adverse effects hav

99 HIV protease inhibitors (PIs) acutely and reversibly inh

100 First-generation HIV protease inhibitors (PIs) alter proteasome activity,

101 Pharmacologic HIV protease inhibitors (PIs) and structurally related o

102 While drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfameth

103 HIV protease inhibitors (PIs) avert apoptosis in part by

104 The use of HIV protease inhibitors (PIs) has been associated with s

105 , and oral administration of prodrugs of the HIV protease inhibitors (PIs) lopinavir and ritonavir.

106 This study examined the effects of HIV protease inhibitors (PIs) on bone resorption, bone f

107 In this article, we show that HIV protease inhibitors (PIs) prescribed to HIV-infected

108 tiretroviral therapy (HAART), which includes HIV protease inhibitors (PIs), has been associated with

109 drug classes such as nucleoside analogs and HIV protease inhibitors (PIs), has increased HIV-patient

110 , which appears to be exacerbated by certain HIV protease inhibitors (PIs).

111 Human immunodeficiency virus (HIV) protease inhibitors (PIs) act as reversible noncomp

112 onstrated that human immunodeficiency virus (HIV) protease inhibitors (PIs) exert inhibitory effects

113 Human immunodeficiency virus (HIV) protease inhibitors (PIs) have been used successful

114 Human immunodeficiency virus (HIV) protease inhibitors (PIs) recently have been report

115 efficacy of 5 human immunodeficiency virus (HIV) protease inhibitors (PIs) was examined by the effec

116 d screening program to discover non-peptidic HIV protease inhibitors previously identified compound I

117 rovide possible cellular mechanisms by which HIV protease inhibitors promote atherosclerosis and card

118 Preclinically, HIV protease inhibitors radiosensitize tumors with activ

119 lues for inhibition of HIV-1 protease by the HIV protease inhibitors ranged from 0.24 nM to 1.0 micro

120 esistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the

121 The design of new HIV protease inhibitors requires an improved understandi

122 nants of CARD8 sensing, we tested a panel of HIV protease inhibitor-resistant clones to establish how

123 anti-retroviral therapies, which incorporate HIV protease inhibitors, resolve many AIDS-defining illn

124 ing to the potent and clinically efficacious HIV protease inhibitor ritonavir are described.

125 or inhibition of glucose transport with the HIV protease inhibitor ritonavir elicited growth arrest

126 lines and primary cells by the FDA-approved HIV protease inhibitor ritonavir, which exerts a selecti

127 The HIV protease inhibitor ritonavir, which inhibits calpain

128 trate that the human immunodeficiency virus (HIV) protease inhibitor ritonavir binds SXR and activate

129 s study, we demonstrate that three different HIV protease inhibitors (ritonavir, indinavir, and ataza

130 daily 10 mg/kg intraperitoneal injection of HIV protease inhibitors (ritonavir, lopinavir/ritonavir

131 The molecular mechanisms of action of a HIV protease inhibitor, ritonavir, on hepatic function w

132 The HIV protease inhibitor, ritonavir, was among 18 compound

133 Ritonavir is a HIV protease inhibitor routinely prescribed to HIV patie

134 inal tyrosine peptide aldehydes based on the HIV protease inhibitors (S)-MAPI and GE 20372 A.

135 Finally, the HIV protease inhibitors saquinavir and ritonavir were po

136 cess an important synthetic precursor to the HIV-protease inhibitor, saquinavir, by formation of an N

137 enzyl P1/P1' moiety of the cyclic urea based HIV protease inhibitor series.

138 Human immunodeficiency virus (HIV) protease inhibitors show activity against Plasmodiu

139 uct FK506, we have synthetically modified an HIV protease inhibitor such that it acquires high affini

140 several potent human immunodeficiency virus (HIV) protease inhibitors such as LY289612.

141 patients with human immunodeficiency virus (HIV) protease inhibitors such as ritonavir can result in

142 chiral building blocks for the synthesis of HIV protease inhibitors, such as atazanavir and darunavi

143 Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected

144 Darunavir is a potent HIV protease inhibitor that has been established as an e

145 We examined the effect of nelfinavir, an HIV protease inhibitor that inhibits Akt signaling, on V

146 , in the presence of dilated cardiomyopathy, HIV protease inhibitors that impair glucose transport in

147 anism by which human immunodeficiency virus (HIV) protease inhibitor therapy adversely induces lipody

148 The potential for HIV protease inhibitors to contribute to or exacerbate c

149 hat it is an important regulator involved in HIV protease inhibitor toxicity and host-microbial patho

150 uran, a high-affinity nonpeptidal ligand for HIV protease inhibitor UIC-94017, is described.

151 hat the combination of posaconazole with the HIV protease inhibitors warrants further investigation a

152 A series of symmetry-based HIV protease inhibitors was designed and synthesized.

153 ivity of three human immunodeficiency virus (HIV) protease inhibitors was investigated in human prima

154 a Merck compound synthesized as a potential HIV protease inhibitor, was investigated using recombina

155 Starting from palinavir (1), our lead HIV protease inhibitor, we have discovered a new series

156 HIV protease inhibitors were developed in the early 1990

157 Several HIV protease inhibitors were found either to inhibit pre

158 rapeutic concentrations (5-15 microM), these HIV protease inhibitors were found to increase the level

159 type 2 diabetes mellitus, and nelfinavir, an HIV protease inhibitor, when used alone or in combinatio

160 d from S-aryl-D-cysteine proved to be potent HIV protease inhibitors which also exhibited potent whol

161 e (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the

162 >4-fold in the presence of ritonavir-boosted HIV protease inhibitors, while pibrentasvir concentratio

163 d UIC-94017 (TMC-114) is a second-generation HIV protease inhibitor with improved pharmacokinetics th

164 ided an example of a promising new series of HIV protease inhibitors with significantly improved enzy

165 mprenavir is a human immunodeficiency virus (HIV) protease inhibitor with a favorable pharmacokinetic

166 template provided a series of highly potent HIV protease inhibitors, with structure-activity relatio

167 le resistance at entry became susceptible to HIV-protease inhibitors within 16 weeks after the discon